Navigation Links
Neurotechnology Launches SkyBiometry Spin-off Company to Deliver SaaS Biometric Identification and Feature Analysis
Date:12/12/2012

VILNIUS, Lithuania, Dec. 12, 2012 /PRNewswire/ -- SkyBiometry, a new company providing cloud-based biometric software as a service (SaaS), was officially launched today as a spin-off of Neurotechnology, a trusted provider of high-precision biometric identification, object recognition and computer vision technologies for more than 20 years. In conjunction with the corporate launch, SkyBiometry introduced a free, cloud-based face detection and recognition API based on a facial recognition algorithm from Neurotechnology, the underlying technology behind many commercial facial recognition products around the world. SkyBiometry also offers a range of paid plans and services to help customers rapidly integrate biometric technologies into their products and online services.

SkyBiometry's team of experienced Neurotechnology professionals have from five to 15 years of experience in algorithm research, biometric solution development and consultancy, enabling them to help customers – even those who are new to biometrics – accelerate product development, integration and time to market. The fast, accurate detection and identification technologies can be used for traditional biometric identification systems such as user ID, security and time management as well as new uses in entertainment, games, online marketing, social media and mobile applications.

"With the launch of SkyBiometry we are pleased to provide cloud-based biometric products and services," said Denis Kocetkov, CEO of SkyBiometry.  "The flexibility and scalability of the SaaS delivery model, together with trusted and proven computer vision technology, creates unique advantages in helping to solve our customers' business needs."

The rapid growth of cloud technologies is creating opportunities for developers and integrators to deliver better products faster than ever before. Because SkyBiometry
'/>"/>

SOURCE SkyBiometry; Neurotechnology
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. NPointer from Neurotechnology Uses Hand Gestures to Control and Navigate Computer Programs Without a Mouse or Touchpad
2. LABS, Inc. Launches Suite of Next-Generation Test Offerings; Focuses on Expanding Complex Biologic Testing Portfolio in 2012
3. Elsevier launches new journal Algal Research
4. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
5. Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes
6. WanderID Launches Breakthrough ID Product for Children, Seniors
7. Wiley-Blackwell launches new open-access journal: Food Science & Nutrition
8. MindSpec launches online Autism Reading Room
9. NineSigma Launches NineSights, the Worlds First Open Innovation Social Media Destination for Innovation Seekers and Solution Providers
10. PuraMed BioScience®, Inc., Launches a Marketing Blitz for LipiGesic® M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDSs Marketplace 2012 Trade Convention
11. NIST launches new website to educate industry about alternatives to mercury thermometers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... soup in which life arose have been maintained in our ... Anglia. , Research published today in the Journal of ... very likely also in animals still perform ancient reactions thought ... some four billion years ago. , The primordial soup theory ... a result of the combination of metals, gases from the ...
(Date:7/24/2014)... in German . ... asthma sufferers worldwide, a further 600 million people living ... global population contending with allergic rhinitis (allergic inflammation of ... other organs and parts of the body beyond the ... the form of inflammatory bowel diseases such as colitis ...
(Date:7/24/2014)... doctors and scientists from Singapore have developed Asia,s first ... eye disease that affects the cornea called corneal stromal ... vision. , Called the POLARIS TGFBI (Transforming Growth ... to aid in the diagnosis and management of patients ... members carrying a TGFBI mutation who may also be ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3
... leaf has revealed the oldest known evidence of a macabre ... to turn them into zombies. The discovery has been ... Hughes, from the University of Exeter, who studies parasites that ... manner of animals are susceptible to the often deadly body ...
... from Mount Sinai School of Medicine have enhanced our ... conversion, the process in which food is converted into ... scientists gain atomic-level insight into how organisms synthesize their ... published in the August issue of PLoS Biology ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
Cached Biology News:Fossil reveals 48-million-year history of zombie ants 2Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4
(Date:7/24/2014)... Texas (PRWEB) July 24, 2014 ... Potassium Sulphate Industry” is a professional and in-depth ... report introduces Potassium Sulphate basic information, including ... and industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment & ...
(Date:7/24/2014)... 24, 2014 The first part of ... in First in Human Studies” will cover comprehensive clinical ... decisions. , With increasing R&D costs and declining industry ... to maximize the knowledge collected in early Phase I/IIa ... success in late stage development. , Next, the presenters ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 As part ... numerous projects in the MENA region during 2014 with ... a preferred provider agreement with DZS to manage our ... region,” said Global VP of R&D and President of ... developed excellent operational practices with a focus on utilizing ...
(Date:7/23/2014)... July 23, 2014  Sangamo BioSciences, Inc. (NASDAQ: ... financial results and accomplishments. For the ... consolidated net loss of $7.0 million, or $0.10 per ... or $0.10 per share, for the same period in ... cash, cash equivalents, marketable securities and interest receivable of ...
Breaking Biology Technology:Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... enhances Microsoft Amalga Life Sciences to accelerate basic research ... June 1 Microsoft Corp. today announced that it ... to acquire certain assets of Rosetta Biosoftware, a business ... of Merck & Co. Inc. The deal allows Microsoft ...
... Move strengthens Kendle,s position as a global clinical ... , CINCINNATI, June 1 Kendle (Nasdaq: ... research organization, today announced the opening of offices ... Philippines. The new operations provide Kendle,s global ...
... , ADHD symptom control demonstrated from the first time ... , PHILADELPHIA, June 1 Shire ... global specialty biopharmaceutical company, today announced that the US ... to the prescribing information for its once-daily Attention Deficit ...
Cached Biology Technology:Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 3Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 2Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7
delta-like 1 homolog (Drosophila)...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: